Abstract
purpose. Defensins are naturally occurring antimicrobial peptides. Recently the
authors published evidence of defensin production by the human
ocular surface. A study was undertaken to look for intraocular
defensins that may account for unexplained antimicrobial activity of
intraocular fluids.
methods. Reverse transcription–polymerase chain reaction (RT–PCR) was
performed on human postmortem ciliary body samples for beta defensins-1
(HBD-1) and beta defensin-2 (HBD-2), and alpha defensins 5 and 6.
Induction of defensins by cytokines was analyzed in cultured human
ciliary body epithelial (CBE) and retinal pigment epithelial (RPE)
cells. Polyclonal antibodies were used to immunoblot aqueous and
vitreous to detect HBD-1 and HBD-2 and to estimate their concentration.
results. RT–PCR revealed constitutive HBD-1 message in ciliary body. HBD-2 and
alpha defensin 5 and 6 messages were absent. HBD-2 message was induced
by cytokine stimulation of both CBE and RPE cells. Immunoblots of
vitreous and aqueous stained positively for HBD-1 but not HBD-2. The
estimated aqueous concentration of HBD-1 was less than 16 ng/ml.
conclusions. This study demonstrates that HBD-1 is constitutively present in the
aqueous and vitreous, probably at sub-bacteriocidal concentrations.
HBD-2 was absent from aqueous, but cytokine stimulation studies suggest
that it may be generated in response to inflammatory cytokines during
infections. HBD-2 has a wider antibacterial spectrum, is 10-fold more
potent, and may play a more significant role in antimicrobial defense
than HBD-1. The use of defensins therapeutically may be indicated;
however, caution is required because defensins also promote cell
proliferation and fibrin formation, which are 2 key elements in ocular
scarring processes such as proliferative
vitreoretinopathy.
The eyes, being constantly exposed to environmental pathogens,
are particularly vulnerable to infection. The protection of the eyes
from microbial attack is of paramount importance, because overwhelming
infection of the cornea or intraocular contents has a devastating
effect on vision. The eye is provided with multiple defense mechanisms,
many of which operate via the tears on the ocular surface and via the
aqueous humor inside the eye.
Defensins are naturally occurring peptides that are considered to be
among the earliest developed molecular effectors of innate
immunity.
1 They are highly conserved molecules present in
many animal classes (mammals, birds, insects, and
amphibians).
2 Defensins have a wide range of antimicrobial
activity encompassing Gram-positive and Gram-negative bacteria, fungi,
and viruses (including human immunodeficiency virus and herpes simplex
virus).
3 4 5 They are also believed to accelerate wound
healing by virtue of their mitogenic effect on epithelial cells and
fibroblasts.
6 7
Two families of mammalian defensins, alpha and beta, have been
described. In humans, alpha defensins are largely present in
polymorphonuclear (PMN) cells (alpha defensins 1 through
4)
8 9 and in the small intestinal Paneth cells (alpha
defensins 5 and 6).
10 11 12 Beta defensins have a wider
cellular distribution than alpha defensins, with human beta defensin-1
(HBD-1) expressed by the pancreas, kidney, and respiratory
epithelium
13 and human beta defensin-2 (HBD-2) recently
demonstrated in the skin.
14
Recent work has shown that the ocular surface expresses a spectrum of
antimicrobial defensins.
15 16 17 Evidence of HBD-1 and HBD-2
production was found in the cornea and conjunctiva, and HBD-1 (but not
HBD-2) was found in the lacrimal gland. Alpha defensins 1 through 4 are
also likely to contribute to ocular surface defense, being released by
PMN cells within the ocular mucosa and tears.
15 16 Evidence of alpha defensin 5 and 6 production was not found on the
ocular surface.
The physiological blood aqueous and blood retinal barriers ensure a
very limited immune cell traffic within the aqueous and vitreous
humors. This should make the intraocular contents particularly
vulnerable to infection. However, intraocular infection, despite the
vast numbers of operations performed (cataract extractions), remains a
surprisingly rare event. The postoperative infection rate after
cataract surgery ranges from 0.022% to 1.42%,
18 19 20 well
below the 7.5% seen in other types of surgery,
21 even
though bacterial contamination of intraocular lenses is in the order of
26%
22 and contamination of anterior chamber aspirates
from eyes that have undergone uncomplicated extracapsular cataract
extraction is in the range of 29% to 43%.
23 24 This led
us to postulate that this antimicrobial effect is related to the
production of intraocular defensins. This theory is supported by work
in other species, which has revealed the presence of a biologically
active antibacterial factor in rabbit aqueous humor.
25 This factor was found to be a peptide of approximately 8 kDa in size
(about double that of defensin). It is possible that the peptide
isolated in this rabbit study was a defensin.
26 A study
was, therefore, undertaken in human eyes to look for intraocular
evidence of the known human alpha and beta defensins.
Seven samples of human ciliary body were taken from cadaveric eyes
donated and consented for transplantation and research and processed
within 48 hours postmortem for total RNA purification so as to maximize
the yield of viable mRNA.
Sixteen aqueous humor samples were obtained, with informed consent,
from patients undergoing cataract surgery, and 7 vitreous humor samples
were obtained from patients undergoing pars plana vitrectomy for a
variety of pathologies including 5 cases of macular hole, 1 epiretinal
membrane, and 1 retinal detachment. Vitreous samples were taken in
preference from patients undergoing vitrectomy for pathologies where
there is minimal contamination of the vitreous with cells not usually
present in the healthy vitreous. Therefore, cases such as extensive
retinal detachment, diabetic vitreous hemorrhage, trauma, and uveitis
were excluded from the study. The vitreous samples were sonicated on
ice to reduce viscosity, before blotting.
An immortalized human nonpigmented ciliary body epithelial cell line
(CBE), which has previously been described,
27 was kindly
donated by Miguel Coca–Prados, PhD (Professor of Research,
Department of Ophthalmology and Visual Science, Yale University School
of Medicine, New Haven, CT). Two cell lines of human retinal pigment
epithelium (RPE) were established from separate cadaveric donors.
At all times the Helsinki agreement as it relates to vitreous and
aqueous donators and the relatives of the donor cadavers was observed
and complied with.
The human CBE cell line was cultured in Primaria tissue
culture flasks (25 cm2 from Falcon;
Becton–Dickinson, Oxford, UK) using Dulbecco’s modified Eagle’s
medium containing 10% fetal bovine serum (FBS). The 2 human RPE cell
lines were cultured in growth medium consisting of Eagle’s minimal
essential medium supplemented with 10% FBS, single-strength
nonessential amino acids, 1 mM sodium pyruvate, 4 mM l-glutamine, and gentamicin (100 μg/ml). Cells were grown
to near confluence in a 5% CO2 incubator at
37°C. The growth medium was replaced with serum-free medium and
culture continued for a further 18 hours. Cells were then stimulated
for 24 hours with either interleukin (IL)-1β, tumor necrosis factor
(TNF)-α, or IL-1β plus TNF-α (PeproTech E.C. Ltd., London, UK) at
a final concentration of 10 ng/ml. Control cultures were run
simultaneously without cytokine stimulation. Cells were harvested with
trypsin EDTA and lysed in buffer containing guanidinium isothiocyanate
and β-mercaptoethanol to denature proteins.
RNA was extracted from the culture cell lysates and from the
postmortem ciliary body samples with the RNeasy Total RNA Kit
(Qiagen, Chatsworth, CA) as per manufacturer’s instructions. cDNA was
then synthesized directly from total RNA using the “Ready to go”
T-Primed First Strand Kit (Pharmacia Biotech, St. Albans, Herts, UK) as
per manufacturer’s instructions.
Adequate cDNA synthesis in each sample was confirmed by including
primers to amplify Hypoxanthine Phospho Ribosyl Transferase cDNA (HPRT,
a low level message produced by all living cells).
The primers used to amplify HBD-1 and HBD-2 and alpha defensin 5
and 6 cDNA were designed on the basis of published genomic DNA and mRNA
sequences (GenBank database accession Nos. X92744, U50930, U50931,
Z71389, M96679, M96682, and M97925): HBD-1 primer sequence, 5′-CCC AGT TCC TGA AAT CCT GA-3′ and 5′-CAG GTG CCT TGA ATT
TTG GT-3′; HBD-2 primer sequence, 5′-CCA GCC ATC AGC CAT GAG
GGT-3′ and 5′-GGA GCC CTT TCT GAA TCC GCA-3′; alpha defensin-5
primer sequence, 5′-ATC CAC TCC TGC TCT CCC TC-3′ and 5′-AGC
AGA GTC TGT AGA GGC GG-3′; alpha defensin-6 primer sequence, 5′-AAC CCT CAC CAT CCT CAC TG-3′ and 5′-TCT GCA ATG GCA AGT
GAA AG-3′ (forward primers italicized). All primers were
intron-spanning, thus making contaminant products derived from genomic
DNA readily detectable.
cDNA (0.5 μl) was added to a mixture (final volume 25 μl) that
contained 0.5 μl dNTP mix (10 mM), 0.25 μl 1% Tween-20, 0.5 μl
of the 3′ and 5′ primers for the relevant defensin (20 μM each), 1μ
l of ELONGASE Enzyme Mix (Taq and Pyrococcus
species GB-D thermostable DNA polymerases; Life Technologies,
Paisley, UK), 5.0 μl 5× Buffer B and 15.75 μl diethyl
pyrocarbonate treated water.
Positive control cDNA samples analyzed included 1 sample from cultured
corneal epithelial cells (HBD-1 and HBD-2), 1 sample from lacrimal
gland (HBD-1 only), and 1 sample from small intestine epithelium
(defensins 5 and 6). The cDNA was replaced with water for the negative
control reaction. PCR amplification was performed with an automated
thermal cycler for 30 cycles using an annealing temperature of 55°C.
Our data suggest that HBD-1 is present at low concentrations (<16
ng/ml) inside the human eye and that the ciliary body and RPE contain
the mRNA necessary for its constitutive manufacture and possible
secretion into the aqueous humor and vitreous. In vitro luminescence
assays with
Escherichia coli DH5α have shown that at the
salt concentration of 150 mM found in the aqueous, the bacteriocidal
concentration of HBD-1 would need to be approximately 12 μg/ml (salt
inhibits the antimicrobial effect of beta defensins).
29 We
estimated the aqueous HBD-1 concentration to be less than 16 ng/ml,
suggesting that the HBD-1 concentration in the aqueous is well below
the reported in vitro bacteriocidal concentration.
The sub-bacteriocidal HBD-1 concentration found in our study mirrors
results in other tissues.
29 30 31 However, despite their low
concentrations, defensins (including HBD-1) may have significant
antimicrobial effects. The high positive charge of defensins may result
in their localization to negatively charged ocular mucous and
epithelia, and this microenvironmental concentrating effect could
elevate the local defensin concentration to effective antimicrobial
levels.
29 Definite evidence of the function of HBD-1 in
the eye remains obscure. Other possible roles could include promotion
of ocular surface healing,
6 7 dendritic and T-cell
chemotaxis,
32 synergistic activity with lysozyme and
lactoferrin,
30 and complement
activation.
33 34
Evidence of intraocular alpha defensins 1 through 4 production was not
sought by RT–PCR in this study, because all tissues containing blood
would be positive because of the alpha defensins 1 through 4 derived
from PMN cells. Tissues containing masses of PMN cells are known to
become saturated with alpha defensins 1 through 4, which even
penetrates structures such as the blood-brain barrier.
35 Therefore breakdown in the blood-ocular barriers during endophthalmitis
or surgery, with the accumulation of intraocular PMN cells would
probably lead to elevated intraocular alpha defensin 1 through 4
levels, adding to the innate antimicrobial response. However, beta
defensins are not produced by leukocytes, and their detection by
RT–PCR in a tissue sample implies their production by the cells of the
tissue and not by the blood cells contained within it.
There was no constitutive expression of HBD-1 in the cultured CBE cell
line and 1 of the RPE cell lines. The other RPE cell line and all the
fresh postmortem ciliary body samples constitutively expressed HBD-1.
This may be related to the downregulation of certain genes after
multiple cell culture passages.
The data on HBD-2 suggested that HBD-2 is not constitutively expressed
inside the human eye, confirmed by both aqueous immunoblots and by
ciliary body and RPE RT–PCR. However, cytokine stimulation studies
suggested that HBD-2 could be generated inside the eye in response to
inflammatory cytokines. Whether the concentration of the HBD-2 produced
by this mechanism is bacteriocidal or bacteriostatic remains to be
discovered. Further studies of aqueous from infected or inflamed eyes
are required to establish whether antimicrobial concentrations of HBD-2
are achieved in eyes challenged by inflammatory stimuli.
The inducibility of HBD-2 but not HBD-1 in cultured CBE and RPE was to
be expected because HBD-2 is known to be inducible by inflammatory
cytokines in other tissues, whereas HBD-1 is not.
13 14 29 This may be because the 5′ flanking region of the genomic HBD-2
sequence contains consensus binding sequences for nuclear factor-κB
(NF-κB), which is implicated in transcriptional responses to
inflammatory cytokines,
36 37 38 suggesting that HBD-2 is
transcriptionally regulated by immunologic stimuli such as IL-1β.
However, the HBD-1 genomic sequence lacks the transcription factor
regulatory elements for NF-κB, making it likely that HBD-1 is not
transcriptionally regulated by inflammatory
agents.
28 29 39 40 41
The inducibility of HBD-2, and the fact that it is approximately
10-fold more potent than HBD-1
29 with a wider
antibacterial spectrum, makes HBD-2 a stronger candidate for
antimicrobial defense in the eye, despite the high salt content of the
ocular fluids. Cytokine-induced HBD-2 production may be more important
for antimicrobial defense than the constitutive HBD-1 production.
In the future purified or recombinant defensins may be useful
therapeutic agents in the eye because they could be applied directly to
the site of infection on the ocular surface or injected into the
aqueous and vitreous during infections. Of particular clinical interest
is that defensins have a broad spectrum of activity, by their unique
mechanism of action may be less susceptible to the development of
bacterial resistance, and appear to be nonantigenic. This contrasts
with most current antibiotics, which have a comparatively limited
spectrum of activity (e.g., Gram-negative bacteria only), interfere
with healing due to ocular toxicity, and sometimes produce allergic
reactions. However, cautious work in the area of the clinical use of
defensins is required, because defensins could also have negative
effects inside the eye. For example, by promoting cellular
proliferation
6 7 and fibrin formation
42 43 defensins could accelerate 2 key events in ocular scarring processes
such as proliferative vitreoretinopathy (PVR).
44 45 Interestingly, the inflammatory cytokines that stimulated RPE cells to
produce HBD-2 in our study, and RPE cells themselves, have also been
found in the vitreous and proliferative membranes of eyes with
PVR.
46 47 48
Supported by a grant from the Royal National Institute for the Blind, UK.
Submitted for publication January 26, 2000; revised March 21 and April 25, 2000; accepted April 27, 2000.
Commercial relationships policy: N.
Corresponding author: Harminder Singh Dua, Department of Ophthalmology, Queen’s Medical Centre, University Hospital, Nottingham NG7 2UH, UK.
[email protected]
The authors thank Gavin Orr (Consultant Ophthalmic Surgeon,
University Hospital Nottingham) for providing vitreous humor samples
and Tomas Ganz and Erika Valore (Department of Medicine and Will Rogers
Institute for Pulmonary Research, University of California at Los
Angeles School of Medicine, Los Angeles, CA) for providing HBD-1– and
HBD-2–purified peptides and antibodies.
Zasloff M. Antibiotic peptides as mediators of innate immunity. Curr Opin Immunol
. 1992;4:3–7.
[CrossRef] [PubMed]Martin E, Ganz T, Lehrer RI. Defensins and other endogenous peptide antibiotics of vertebrates. J Leukoc Biol
. 1995;58:128–136.
[PubMed]Lehrer RI, Lichtenstein AK, Ganz T. Defensins: antimicrobial and cytotoxic peptides of mammalian cells. Annu Rev Immunol
. 1993;11:105–128.
[CrossRef] [PubMed]Daher KA, Selsted ME, Lehrer RI. Direct inactivation of viruses by human granulocyte defensins. J Virol
. 1986;60:1068–1074.
[PubMed]Nakashima H, Yamamoto N, Masuda M, Fujii N. Defensins inhibit HIV replication in vitro. Aids
. 1993;7:1129.
[CrossRef] [PubMed]Murphy CJ, Foster BA, Mannis MJ, Selsted ME, Reid TW. Defensins are mitogenic for epithelial cells and fibroblasts. J Cell Physiol
. 1993;155:408–413.
[CrossRef] [PubMed]Kudryashov BA, Kondashevskay MV, Lyapina LA, et al. Action of defensin on healing of aseptic skin wounds and vascular permeability. Bull Exp Biol Med
. 1990;109:513–515.
[CrossRef] Ganz T, Selsted ME, Szklarek D, et al. Defensins: natural peptide antibiotics of human neutrophils. J Clin Invest
. 1985;76:1427–1435.
[CrossRef] [PubMed]Selsted ME, Miller SI, Henschen AH, Ouellette AJ. Enteric defensins: antibiotic peptide components of intestinal host defence. J Cell Biol
. 1992;118:929–936.
[CrossRef] [PubMed]Jones DE, Bevin CL. Paneth cells of the human small intestine express an antimicrobial peptide gene. J Biol Chem
. 1992;267:23216–23225.
[PubMed]Jones DE, Bevins CL. Defensin-6 m-RNA in human Paneth cells: implications for antimicrobial peptides in the host defense of the human bowel. FEBS Lett
. 1993;315:187–192.
[CrossRef] [PubMed]Zhao C, Wang I, Lehrer RI. Widespread expression of beta-defensin hBD-1 in human secretory glands and epithelial cells. FEBS Lett
. 1996;396:319–322.
[CrossRef] [PubMed]Harder J, Bartels J, Christophers E, Schroder J–M. A peptide antibiotic from human skin. Nature
. 1997;387:861.
[CrossRef] [PubMed]Haynes RJ, Tighe PJ, Dua HS. Innate defence of the eye by antimicrobial defensin peptides. Lancet. 1998;352:451–452.
Haynes RJ, Tighe PJ, Dua HS. Antimicrobial defensin peptides of the human ocular surface. Br J Ophthalmol
. 1999;83:737–741.
[CrossRef] [PubMed]Gottsch JD, Li Q, Ashraf MF, O’Brien TP, Stark WJ, Liu SH. Defensin gene expression in the cornea. Curr Eye Res
. 1998;17:1082–1086.
[CrossRef] [PubMed]Norregaard JC, Thoning H, Bernth–Petersen P, Andersen TF, Javitt JC, Anderson GF. Risk of endophthalmitis after cataract extraction: results from the International Cataract Surgery Outcomes study. Br J Ophthalmol
. 1997;81:102–106.
[CrossRef] [PubMed]Jenkins CD, McDonnell PJ, Spalton DJ. Randomised single blind trial to compare the toxicity of subconjunctival gentamicin and cefuroxime in cataract surgery. Br J Ophthalmol
. 1990;74:734–738.
[CrossRef] [PubMed]Meyers–Elliott RH, Dethlefs BA. Experimental
Klebsiella-induced endophthalmitis in the rabbit. Arch Ophthalmol
. 1982;100:1959–1963.
[CrossRef] [PubMed]Brote L, Gillquist J, Tarnvik A. Wound infections in general surgery: wound contamination, rates of infection and some consequences. Acta Chir Scand
. 1976;142:99–106.
[PubMed]Vafidis GC, Marsh RJ, Stacey AR. Bacterial contamination of intraocular lens surgery. Br J Ophthalmol
. 1984;68:520–523.
[CrossRef] [PubMed]Sherwood DR, Rich WJ, Jacob JS, Hart RJ, Fairchild YL. Bacterial contamination of intraocular and extraocular fluids during extracapsular cataract extraction. Eye
. 1989;3:308–312.
[CrossRef] [PubMed]Dickey JB, Thompson KD, Jay WM. Anterior chamber aspirate cultures after uncomplicated cataract surgery. Am J Ophthalmol
. 1991;112:278–282.
[CrossRef] [PubMed]Diamond JP, Leeming JP, Smart AD, Duffus P, Hedges AJ, Easty DL. An antimicrobial effect associated with rabbit primary aqueous humor. Br J Ophthalmol
. 1994;78:142–148.
[CrossRef] [PubMed]Diamond JP, Moule K, Leeming JP, Tavare J, Easty DL. Purification of an antimicrobial peptide from rabbit aqueous humor. Curr Eye Res
. 1998;17:783–787.
[CrossRef] [PubMed]Martin–Vasallo P, Ghosh S, Coca–Prados M. Expression of Na, K-ATPase alpha subunit isoforms in the human ciliary body and cultured ciliary epithelial cells. J Cell Physiol
. 1989;141:243–252.
[CrossRef] [PubMed]Valore EV, Park CH, Quayle AJ, Wiles KR, McCray PB, Jr, Ganz T. Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. J Clin Invest
. 1998;101:1633–1642.
[CrossRef] [PubMed]Singh PK, Jia HP, Wiles K, et al. Production of beta-defensins by human airway epithelia. Proc Natl Acad Sci USA
. 1998;95:14961–14966.
[CrossRef] [PubMed]Bals R, Wang X, Wu Z, et al. Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest
. 1998;102:874–880.
[CrossRef] [PubMed]Zucht HD, Grabowsky J, Schrader M, et al. Human beta-defensin-1: a urinary peptide present in variant molecular forms and its putative functional implication. Eur J Med Res
. 1998;3:315–323.
[PubMed]Yang D, Chertov O, Bykovskaia SN, et al. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science
. 1999;286:525–528.
[CrossRef] [PubMed]Prohaszka Z, Nemet K, Csermely P, Hudecz F, Mezo G, Fust G. Defensins purified from human granulocytes bind C1q and activate the classical complement pathway like the transmembrane glycoprotein gp41 of HIV-1. Mol Immunol
. 1997;34:809–816.
[CrossRef] [PubMed]Prohaszka Z, Fust G. Contribution of complement to defensin action in the eye (Letter). Lancet. 1998;352:1152.
Schluesener H, Meyermann R. Neutrophilic defensins penetrate the blood-brain barrier. J Neurosci Res
. 1995;42:718–723.
[CrossRef] [PubMed]Liu L, Wang L, Jia HP, et al. Structure and mapping of the human beta-defensin HBD-2 gene and its expression at sites of inflammation. Gene
. 1998;222:237–244.
[CrossRef] [PubMed]Shi RJ, Simpson–Haidaris PJ, Lerner NB, Marder VJ, Silverman DJ, Sporn LA. Transcriptional regulation of endothelial cell tissue factor expression during
Rickettsia rickettsii infection: involvement of the transcription factor NF-kappaB. Infect Immun
. 1998;66:1070–1075.
[PubMed]Diamond G, Jones DE, Bevins CL. Airway epithelial cells are the site of expression of a mammalian antimicrobial peptide gene. Proc Natl Acad Sci USA
. 1993;90:4596–4600.
[CrossRef] [PubMed]Liu L, Zhao C, Heng HH, Ganz T. The human beta-defensin-1 and alpha-defensins are encoded by adjacent genes: two peptide families with differing disulfide topology share a common ancestry. Genomics
. 1997;43:316–320.
[CrossRef] [PubMed]Schroder JM, Harder J. Human beta-defensin-2. Int J Biochem Cell Biol
. 1999;31:645–651.
[CrossRef] [PubMed]Schroder JM. Clinical significance of epithelial peptide antibiotics. BioDrugs
. 1999;11:293–300.
[CrossRef] [PubMed]Higazi AA–R, Barghouti II, Abu–Much R. Identification of an inhibitor of tissue-type plasminogen activator- mediated fibrinolysis in human neutrophils: a role for defensin. J Biol Chem
. 1995;270:9472–9477.
[CrossRef] [PubMed]Higazi AA–R, Ganz T, Kariko K, Cines DB. Defensin modulates tissue-type plasminogen activator and plasminogen binding to fibrin and endothelial cells. J Biol Chem
. 1996;271:17650–17655.
[CrossRef] [PubMed]Charteris DG. Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol
. 1995;79:953–960.
[CrossRef] [PubMed]Charteris DG. Growth factors in proliferative vitreoretinopathy. Br J Ophthalmol
. 1998;82:106.
[CrossRef] [PubMed]Limb GA, Little BC, Meager A, et al. Cytokines in proliferative vitreoretinopathy. Eye
. 1991;5:686–693.
[CrossRef] [PubMed]Limb GA, Earley O, Jones SE, LeRoy F, Chignell AH, Dumonde DC. Expression of mRNA coding for TNF alpha, IL-1 beta and IL-6 by cells infiltrating retinal membranes. Graefes Arch Clin Exp Ophthalmol
. 1994;232:646–651.
[CrossRef] [PubMed]El-Ghrably IA, Dua HS, Orr GM, Fischer D, Tighe PJ. Detection of cytokine mRNA production in infiltrating cells in proliferative vitreoretinopathy using reverse transcription polymerase chain reaction. Br J Ophthalmol
. 1999;83:1296–1299.
[CrossRef] [PubMed]